From Yahoo Finance: 2025-03-27 09:38:00

Shares of Zoetis have been affected by Q4 earnings and revenue guidance falling short. Competitors entering the market in 2025 could impact revenue. Potential product approvals for chronic kidney disease and oncology in dogs may drive growth worth up to $5.7 billion. Consider long-term potential before investing.



Read more at Yahoo Finance: Zoetis’ Stock Is About as Cheap as It’s Ever Been. 1 Thing to Know Before You Buy.